Key points are not available for this paper at this time.
This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the complex considerations of outcomes and value that should justify the pricing.
Bach et al. (Tue,) studied this question.